Transmucosal Drug Delivery Gaining Interest in Niche Markets

Transmucosal Drug Delivery Gaining Interest in Niche Markets

(openPR) - (Amherst, NH) - In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery, which includes buccal tablets and films, oral spray and sublingual films and wafers, offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. The technology is attracting interest as drug developers search for ways to address demographic shifts and prescribing trends while re-positioning proprietary drugs approaching the end of patent life.

Demand for transmucosal drug delivery will benefit from several converging market forces. The shifting population demographics in developed societies will drive an increasing demand for palliative treatments associated with an aging patient base. Continuing efforts to control rising healthcare costs in many western countries will place a greater emphasis on home health care and self-administration of drug therapies for chronic conditions such as pain management and hormone replacement therapy.

A new report that presents a comprehensive assessment of the current status of transmucosal drug products and the prospects for late-stage development candidates has just been published. The report - Transmucosal Drug Delivery: Markets & Prospects for Films, Sprays, Lozenges, Wafers & Tablets - contains insightful analysis of transmucosal delivery technology and products, assessments of pipeline drugs, profiles of transmucosal market participants, industry data and forecasts, and detailed analysis of regulatory and market factors. Organized and written to be of maximum value to pharmaceutical professionals, drug delivery market participants, and healthcare investors, the report contains all of the information necessary to understand the growing potential of transmucosal drug delivery in selected therapeutic markets.

More information is available at www.greystoneassociates.org .

Source: Greystone Research Associates

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.